Chemotherapy and Targeted Therapy

From Trial-and-Error to Precision Engineering: Cellular Intelligence Takes the Reins of Novo Nordisk’s Parkinson’s Program from-trial-and-error-to-precision-engineering-cellular-intelligence-takes-the-reins-of-novo-nordisks-parkinsons-program

From Trial-and-Error to Precision Engineering: Cellular Intelligence Takes the Reins of Novo Nordisk’s Parkinson’s Program

Lina Irawan June 23, 2026

In a landmark deal that signals a shifting tide in the biotech sector, the startup Cellular Intelligence...

The Critical Two Weeks: Mastering the Specialty Pharmacy Patient Journey the-critical-two-weeks-mastering-the-specialty-pharmacy-patient-journey

The Critical Two Weeks: Mastering the Specialty Pharmacy Patient Journey

Laily UPN June 23, 2026

In the modern era of medicine, the therapeutic success of a breakthrough drug is no longer determined...

The Silent Crisis: Why the Biopharma Industry is Losing Its Most Valuable Asset During Tech Transfer female technician in laboratory of genetics - reprogenetics

female technician in laboratory of genetics - reprogenetics

The Silent Crisis: Why the Biopharma Industry is Losing Its Most Valuable Asset During Tech Transfer

Sagoh June 23, 2026

In the high-stakes world of biopharmaceutical manufacturing, the term "technology transfer" often conjures images of seamless data...

Pharma Industry Weekly: Leadership Shifts, Late-Stage Successes, and Strategic Funding Rounds pharma-industry-weekly-leadership-shifts-late-stage-successes-and-strategic-funding-rounds

Pharma Industry Weekly: Leadership Shifts, Late-Stage Successes, and Strategic Funding Rounds

Laily UPN June 22, 2026

The global pharmaceutical landscape is currently navigating a period of profound transition. From high-level C-suite departures at...

The Pharma Paradox: Sustainability Ambitions Clash with Rising Global Emissions the-pharma-paradox-sustainability-ambitions-clash-with-rising-global-emissions

The Pharma Paradox: Sustainability Ambitions Clash with Rising Global Emissions

Asep Darmawan June 22, 2026

The healthcare industry, a sector defined by its mission to save lives, is increasingly grappling with a...

Beyond the Initial Impact: The Convergence of TBI and Alzheimer’s Research and the Promise of Next-Generation Immunotherapy beyond-the-initial-impact-the-convergence-of-tbi-and-alzheimers-research-and-the-promise-of-next-generation-immunotherapy

Beyond the Initial Impact: The Convergence of TBI and Alzheimer’s Research and the Promise of Next-Generation Immunotherapy

Neng Nana June 22, 2026

Traumatic Brain Injury (TBI) is often perceived as a singular event—a collision, a fall, or a strike....

The Double-Edged Sword of Retatrutide: Balancing Unprecedented Efficacy with New Safety Challenges the-double-edged-sword-of-retatrutide-balancing-unprecedented-efficacy-with-new-safety-challenges

The Double-Edged Sword of Retatrutide: Balancing Unprecedented Efficacy with New Safety Challenges

Asep Darmawan June 22, 2026

In the rapidly evolving landscape of metabolic medicine, Eli Lilly has positioned itself at the vanguard with...

Race Against Time: CEPI Accelerates Global Response to Bundibugyo Ebolavirus Outbreak race-against-time-cepi-accelerates-global-response-to-bundibugyo-ebolavirus-outbreak-1

Race Against Time: CEPI Accelerates Global Response to Bundibugyo Ebolavirus Outbreak

Layla Zulfa June 21, 2026

In a critical move to curb the spread of the Bundibugyo ebolavirus (BDBV) currently impacting the Democratic...

Retatrutide’s Triple-Threat: Eli Lilly’s New Clinical Data Redefines the Obesity Treatment Paradigm retatrutides-triple-threat-eli-lillys-new-clinical-data-redefines-the-obesity-treatment-paradigm

Retatrutide’s Triple-Threat: Eli Lilly’s New Clinical Data Redefines the Obesity Treatment Paradigm

Muslim June 21, 2026

In the rapidly evolving landscape of metabolic medicine, Eli Lilly has achieved a decisive breakthrough that positions...

Shifting the Paradigm: How ADME-One is Moving Human PK Projections to the Start of the Drug Discovery Funnel shifting-the-paradigm-how-adme-one-is-moving-human-pk-projections-to-the-start-of-the-drug-discovery-funnel

Shifting the Paradigm: How ADME-One is Moving Human PK Projections to the Start of the Drug Discovery Funnel

Asep Darmawan June 21, 2026

In the traditional landscape of small-molecule drug discovery, the timeline is often dictated by a rigid, linear...

Chemotherapy and Targeted Therapy

From Trial-and-Error to Precision Engineering: Cellular Intelligence Takes the Reins of Novo Nordisk’s Parkinson’s Program

The Critical Two Weeks: Mastering the Specialty Pharmacy Patient Journey

The Silent Crisis: Why the Biopharma Industry is Losing Its Most Valuable Asset During Tech Transfer

Pharma Industry Weekly: Leadership Shifts, Late-Stage Successes, and Strategic Funding Rounds

The Pharma Paradox: Sustainability Ambitions Clash with Rising Global Emissions

Beyond the Initial Impact: The Convergence of TBI and Alzheimer’s Research and the Promise of Next-Generation Immunotherapy

The Double-Edged Sword of Retatrutide: Balancing Unprecedented Efficacy with New Safety Challenges

Race Against Time: CEPI Accelerates Global Response to Bundibugyo Ebolavirus Outbreak

Retatrutide’s Triple-Threat: Eli Lilly’s New Clinical Data Redefines the Obesity Treatment Paradigm

Shifting the Paradigm: How ADME-One is Moving Human PK Projections to the Start of the Drug Discovery Funnel

You may have missed

Ibuprofen: Beyond Pain Relief – Unveiling its Unexpected Anti-Cancer Potential

A Paradigm Shift in HIV Care: Gilead and Merck’s Once-Weekly Regimen Passes Phase 3 Milestone

Beyond Wrinkles: The Emerging Role of Botox in Revolutionizing Scar Management

The Radiology Crisis: Escalating Costs and Workforce Shortages Threaten Patient Care